ProMIS Neurosciences EV/EBITDA
What is the EV/EBITDA of ProMIS Neurosciences?
The EV/EBITDA of ProMIS Neurosciences, Inc. is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on OTC compared to ProMIS Neurosciences
What does ProMIS Neurosciences do?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Companies with ev/ebitda similar to ProMIS Neurosciences
- Good2 Go4 Corp has EV/EBITDA of N/A
- 3D Resources has EV/EBITDA of N/A
- Litian Pictures has EV/EBITDA of N/A
- Dimerix has EV/EBITDA of N/A
- Inogen Inc has EV/EBITDA of N/A
- Taung Gold International has EV/EBITDA of N/A
- ProMIS Neurosciences has EV/EBITDA of N/A
- China Youzan has EV/EBITDA of N/A
- PanAsialum has EV/EBITDA of N/A
- Damstra Ltd has EV/EBITDA of N/A
- IDT International has EV/EBITDA of N/A
- Kalytera Therapeutics has EV/EBITDA of N/A
- Purepoint Uranium has EV/EBITDA of N/A